Abstract
Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2), known to cause Coronavirus disease 2019 (COVID-19), is a new strain of Coronavirus which was first reported in the Wuhan city of China in December 2019. COVID-19 has shown to increase the risk for thrombotic or thromboembolic events by altering the prothrombotic factor levels and direct endothelial cell invasion. Deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), and stroke have been more commonly reported, and incidence of these events is noted to be higher in patients with severe infection. Here we describe a case of a 38-year-old male with mild, self-limiting COVID-19 who developed an isolated renal infarction. He tested positive for Lupus Anticoagulant (LAC). The role of autoantibodies like LAC as a risk factor for thrombotic complications is a topic of debate and needs to be studied further. This uncommon case warrants identification of patients who might be at a higher risk for thrombotic events even with milder forms of COVID-19, and following and managing such patients closely.
Keywords
Coronavirus/COVID-19, Infarction, Kidney diseases, Lupus coagulation inhibitor, Thrombosis/thromboembolism